Fulgent narrows 2026 loss guidance

 

Fulgent narrows 2026 loss guidance as Q3 revenue rises 8% YoY to $90.4M, non-GAAP loss $0.09, margins recover sequentially

• Q3 2026 revenue grew 8% YoY and 6% QoQ to $90.4 million, beating analyst revenue estimates.
• Q3 non-GAAP loss was $0.09 as operating margin improved sequentially from -26.2% to -13.2%, showing significant operational progress.
• Billing and revenue cycle transition still depresses collections, but trends improved meaningfully in Q3.
• Full-year 2026 revenue guidance $330–340 million reaffirmed, and non-GAAP loss per share guidance narrowed, improving loss outlook.
• Precision diagnostics declined 18% YoY; anatomic pathology grew 57% YoY, driven by acquisitions.
• AI pathology platform analyzed 255,000 slides, +23% QoQ, with just 0.01% failure.
• Therapeutic pipeline progressed: FID-07 preparing Phase 3; FID-022 nearing maximum tolerated dose.
• Cash balance reached $652 million after tax refund; company expects ~$630 million year-end, supporting an improved cash outlook.
• Management tone confident but cautious, emphasizing continued RCM work and disciplined operating expenses.
• Q&A focused on billing normalization timing, Q4 revenue trajectory, and AI/Bako integration benefits.
• Main concern: speed and completeness of revenue cycle recovery to restore historical collection rates and profitability.
• Mixed quarter, driven by improving margins and cash outlook amid ongoing billing-system normalization challenges.

https://finviz.com/stock?t=FLGT&p=d